FBFrancesco Barale

Francesco Barale

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Francesco Barale has a total of 285 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pharmacological Modulation of GABA Function in Autism Spectrum Disorders: A Systematic Review of Human Studies

    by Natascia Brondino, Laura Fusar-Poli, Cristina Panisi, Stefano Damiani, Francesco Barale, Pierluigi Politi

    Autism spectrum disorders are an emerging health problem worldwide, but little is known about their pathogenesis. It has been hypothesized that autism may result from an imbalance between excitatory glutamatergic and inhibitory GABAergic pathways. Commonly used medications such as valproate, acamprosate, and arbaclofen may act on the GABAergic system and be a potential treatment for people with ASD. The present systematic review aimed at evaluating the state-of-the-art of clinical trials of GABA modulators in autism. To date there is insufficient evidence to suggest the use of these drugs in autistic subjects, even if data are promising. Of note, short-term use of all the reviewed medications appears to be safe. Future well designed trials are needed to elucidate these preliminary findings.


  • Open Access

    Complementary and Alternative Therapies for Autism Spectrum Disorder

    by Natascia Brondino, Laura Fusar-Poli, Matteo Rocchetti, Umberto Provenzani, Francesco Barale, Pierluigi Politi

    Background. Complementary and alternative medicine (CAM) represents a popular therapeutic option for patients with autism spectrum disorder (ASD). Unfortunately, there is a paucity of data regarding the efficacy of CAM in ASD. The aim of the present systematic review is to investigate trials of CAM in ASD.Material and Methods. We searched the following databases: MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, CINAHL, Psychology and Behavioral Sciences Collection, Agricola, and Food Science Source.Results. Our literature search identified 2687 clinical publications. After the title/abstract screening, 139 publications were obtained for detailed evaluation. After detailed evaluation 67 studies were included, from hand search of references we retrieved 13 additional studies for a total of 80.Conclusion. There is no conclusive evidence supporting the efficacy of CAM therapies in ASD. Promising results are reported for music therapy, sensory integration therapy, acupuncture, and massage.


  • Open Access

    Curcumin as a Therapeutic Agent in Dementia: A Mini Systematic Review of Human Studies

    by Natascia Brondino, Simona Re, Annalisa Boldrini, Antonella Cuccomarino, Niccolò Lanati, Francesco Barale, Pierluigi Politi

    Dementia is a leading health problem worldwide, with Alzheimer’s disease (AD) representing up to 60% of all dementia cases. A growing interest has recently risen on the potential use of natural molecules in this condition. Curcumin is a polyphenolic compound traditionally used in Indian medicine. Severalin vitroandin vivostudies have found a protective effect of curcumin in AD. In the present systematic review we aimed to evaluate the state-of-the-art of clinical trials of curcumin in AD. We retrieved three published studies, while there are several ongoing clinical trials. To date there is insufficient evidence to suggest the use of curcumin in dementia patients. Of note, short-term use of curcumin appears to be safe. Several reasons could be responsible for the discrepancy betweenin vitroandin vivofindings and human trials, such as low bioavailability and poor study design.


  • Childhood abuse is associated with structural impairment in the ventrolateral prefrontal cortex and aggressiveness in patients with borderline personality disorder

    by Niccolò Morandotti, Danai Dima, Jigar Jogia, Sophia Frangou, Michela Sala, Giulia Zelda De Vidovich, Matteo Lazzaretti, Francesca Gambini, Elisa Marraffini, Giorgio D'Allio, et al.


  • Randomized placebo-controlled trials of omega-3 polyunsaturated fatty acids in psychiatric disorders: a review of the current literature.

    by Pierluigi Politi, Matteo Rocchetti, Enzo Emanuele, Mariangela Rondanelli, Francesco Barale

    Abstract: A growing body of evidence suggests that omega (ω)-3 polyunsaturated fatty acids (PUFAs) are clinically useful in patients with psychiatric disorders. In the present review, we summarize the findings of randomized, placebocontrolled clinical trials that have focused on the potential therapeutic utility of ω-3 PUFAs in patients with mental illnesses. We searched the PubMed database for placebo-controlled clinical trials using the keywords “PUFAs”, “omega-3”, “eicosapentaenoic acid”, and “docosahexaenoic acid” in combination with the following terms: “anxiety disorders”, “mood disorders”, “autism”, “attention-deficit hyperactivity disorder” (ADHD), “personality disorders”, and “schizophrenia”. The literature review indicated that personality disorders, autism, and anxiety disorders have been investigated less frequently than mood disorders, schizophrenia, and ADHD. Although no definite conclusions can be drawn on the therapeutic efficacy of ω-3 PUFAs in the majority of the psychiatric illnesses examined here, the evidence suggests that these molecules have a potential preventive role in people at extremely high risk for developing psychosis. Future studies in the field should examine ω-PUFAs turnover in neural membranes. Moreover, special attention should be paid to potential confounds, such as smoking and dietary habits.


  • Association between Low-Activity Allele of Cathecolamine-O-Methyl-Transferase (COMT) and Borderline Personality Disorder in an Italian Population

    by Matteo Lazzaretti, Dora Fabbro, Michela Sala, Kether Del Toso, Giulia de Vidovich, Elisa Marraffini, Niccolò Morandotti, Francesca Gambini, Francesco Barale, Matteo Balestrieri, et al.

    The objective of the present study was to test the association between Borderline Personality Disorder (BPD) and the cathecolamine-O-methyl-transferase (COMT) low-activity (Met158) single nucleotide polymorphism (SNP). In this case-control study, DNA was obtained from venous blood of 19 BPD patients and 36 healthy subjects. COMT-Val158Met single-nucleotide polymorphism was genotyped by predesigned SNP assay. The COMT Met158 allele was over-represented in patients with BPD in comparison to normal subjects (68.4% vs 44.4%, respectively; Fisher exact test, p = .02). In terms of genotype, the Met158Met subjects were more frequent in patients versus controls (47.4% vs 22.2%, respectively), whereas the high-activity genotype Val158Val was under-represented (10.5% vs 33.3%, respectively). The allele encoding for the COMT with low enzymatic efficiency was found to be over-represented in BPD, possibly resulting in excessive synaptic dopaminergic activity and ultimately affecting externalizing behaviours, such as impulsivity and aggressiveness.


  • Open Access

    The Recovery Orientation of a Farm Community for Severe Autism — Data from the DREEM-IT (Developing Recovery Enhancing Environment Measures — Italian Version)

    by Marianna Boso, Enzo Emanuele, Elizabeth Barron, Noemi Piaggi, Giulia Scanferla, Matteo Rocchetti, Umberto Provenzani, Davide Broglia, Paolo Orsi, Roberto Colombo, et al.

  • Impaired working memory and normal sustained attention in borderline personality disorder

    by Matteo Lazzaretti, Niccolò Morandotti, Michela Sala, Miriam Isola, Sophia Frangou, Giulia De Vidovich, Elisa Marraffini, Francesca Gambini, Francesco Barale, Federico Zappoli, et al.

    Lazzaretti M, Morandotti N, Sala M, Isola M, Frangou S, De Vidovich G, Marraffini E, Gambini F, Barale F, Zappoli F, Caverzasi E, Brambilla P. Impaired working memory and normal sustained attention in borderline personality disorder.Objective: Although reports in the literature describe deficits in working memory in borderline personality disorder (BPD), the evidence is limited and inconsistent. The aim of this study was to evaluate further this cognitive dimension and its clinical correlates in BPD.Method: We compared the performance of 15 BPD patients to 1:1 matched healthy controls on verbal working memory as determined by the sequential letter N-back test and sustained attention as measured using the continuous performance test (CPT).Results: BPD patients performed significantly worse on the N-back test compared to healthy controls (p < 0.05), but not on the CPT. The N-back deficit was more pronounced and significant in the 3-back condition and inversely correlated with impulsivity.Conclusions: These results suggest the presence of working memory deficits in BPD that may be linked to greater impulsivity and sustained by impairment in the dorsolateral prefrontal cortex.


    • 13 June 2012
      • Vol. 27  (1) , 13-22

    Magnetic resonance spectroscopy in the evaluation of treatment efficacy in unipolar major depressive disorder: a review of the literature.

    by Eduardo Caverzasi, Anna Pichiecchio, Guy Umberto Poloni, Alessandro Calligaro, Moreno Pasin, Fulvia Palesi, Gloria Castellazzi, Massimo Pasquini, Massimo Biondi, Francesco Barale, et al.

    More and more neuroimaging studies are using in vivo proton magnetic resonance spectroscopy (1H-MRS) to explore correlates of response to therapy in major depressive disorder (MDD). Their aim is to further understanding of the effects of neurotransmitter changes in areas involved in MDD and the mechanisms underlying a good treatment response. We set out to summarise the literature from the past fifteen years on biochemical correlates of treatment response in MDD patients, reflected in pre- and post-therapy changes in 1H-MRS measurements. Our literature search identified fifteen articles reporting 1H-MRS studies in MDD treatment; no study used 1P-MRS. Despite the wide diversity of 1H-MRS methods applied, brain regions studied, and metabolite changes found, there emerged strong evidence of a correlation between changes in neurometabolite concentrations, in particular glutamate, N-acetylaspartate and choline, and a good treatment response to pharmacotherapy or antidepressant stimulation techniques.


  • Top Cited Papers
    Open Access

    Predicting Psychosis

    by Paolo Fusar-Poli, Ilaria Bonoldi, Alison R. Yung, Stefan Borgwardt, Matthew J. Kempton, Lucia Valmaggia, Francesco Barale, Edgardo Caverzasi, Philip McGuire

    Although prodromal symptoms of psychosis have long been recognized,2 the clinical management of psychotic disorders conventionally begins at the first episode of frank psychosis, and, until recently, the period immediately preceding the first episode received relatively little attention. For the past 15 years, there has been increasing academic and clinical interest in people presenting with potentially prodromal symptoms.3 This clinical syndrome has been termed an at risk mental state,4 and operationalized criteria—the ultra high risk (UHR)5 or clinical high risk (HR)6 criteria—have been developed to identify the syndrome.4 The criteria apply to young help-seeking patients and require 1 of 3 presentations:“attenuated” psychotic symptoms, full-blown psychotic symptoms that are brief and self-limiting, or a significant decrease in functioning in the context of a genetic risk for schizophrenia.7 Additional prodromal criteria emerging from the basic symptoms (BS) literature8 include subjective disturbances of cognitive processing and the perception of the self and the world.9 Belonging to one of these prodromal groups, which we hereafter term the clinical high risk syndrome, is associated with impairments in neuropsychologic performance10 and alterations in the structure11-13 (for meta-analyses, see Fusar-Poli et al14,15), function16-18 (for meta-analyses, see Smieskova et al19 and Fusar-Poli et al20), connectivity,21 and neurochemistry22-24 of the brain.